Mifepristone's effectiveness for cervical ripening in midtrimester abortions explored before oxytocin induction.

Induction of midtrimester abortion requires both cervical ripening and subsequent uterine contraction. Current protocols frequently rely on prostaglandins (PG), which are associated with uncomfortable side effects and are contraindicated in women with a history of cesarean section. This creates a clinical need for alternative, safer ripening agents. Mifepristone, an antiprogesterone drug, has established use in first and second-trimester abortion induction, suggesting its potential for cervical preparation. This study aims to investigate Mifepristone's utility for cervical ripening before subsequent high-dose Oxytocin administration.

This exploratory study's primary objective was to investigate the effectiveness of Mifepristone for cervical ripening. The research design focused on evaluating its utility as a preparatory step before the administration of high-dose Oxytocin drip to induce uterine evacuation. No specific patient cohort size, dosing regimen, route of administration, or duration of treatment for Mifepristone were detailed in the provided abstract. The study's aim was to determine if Mifepristone could serve as an effective agent for cervical preparation.